DexCom (DXCM) Lowered to Buy at ValuEngine

ValuEngine downgraded shares of DexCom (NASDAQ:DXCM) from a strong-buy rating to a buy rating in a research note released on Monday, ValuEngine reports.

DXCM has been the subject of several other research reports. Cowen increased their price objective on shares of DexCom from $150.00 to $175.00 and gave the stock an outperform rating in a research report on Friday, February 22nd. Morgan Stanley increased their price objective on shares of DexCom from $135.00 to $160.00 and gave the stock an equal weight rating in a research report on Monday, February 25th. Canaccord Genuity increased their price objective on shares of DexCom from $140.00 to $160.00 and gave the stock a buy rating in a research report on Friday, February 22nd. BidaskClub raised shares of DexCom from a hold rating to a buy rating in a research report on Friday, December 28th. Finally, Piper Jaffray Companies increased their price objective on shares of DexCom to $165.00 and gave the stock an overweight rating in a research report on Wednesday, January 9th. Seven analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. DexCom has a consensus rating of Buy and a consensus price target of $149.53.

NASDAQ:DXCM opened at $115.17 on Monday. The company has a current ratio of 7.64, a quick ratio of 7.32 and a debt-to-equity ratio of 1.52. The company has a market cap of $10.72 billion, a price-to-earnings ratio of 383.90 and a beta of 0.76. DexCom has a fifty-two week low of $69.51 and a fifty-two week high of $156.16.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Thursday, February 21st. The medical device company reported $0.54 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.16 by $0.38. The company had revenue of $338.00 million for the quarter, compared to the consensus estimate of $331.60 million. DexCom had a negative net margin of 12.32% and a positive return on equity of 4.98%. DexCom’s revenue was up 52.9% on a year-over-year basis. During the same quarter last year, the firm posted $0.10 earnings per share. On average, equities analysts predict that DexCom will post 0.46 earnings per share for the current fiscal year.

In other DexCom news, SVP Patrick Michael Murphy sold 400 shares of the firm’s stock in a transaction on Thursday, January 10th. The shares were sold at an average price of $138.75, for a total transaction of $55,500.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Steven Robert Pacelli sold 3,114 shares of the firm’s stock in a transaction on Wednesday, January 23rd. The stock was sold at an average price of $149.74, for a total transaction of $466,290.36. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 105,679 shares of company stock valued at $15,043,754. Company insiders own 1.80% of the company’s stock.

A number of hedge funds have recently made changes to their positions in the business. American Century Companies Inc. bought a new position in shares of DexCom in the 4th quarter worth about $13,436,000. Norges Bank bought a new stake in DexCom in the 4th quarter valued at about $107,191,000. Dimensional Fund Advisors LP lifted its position in DexCom by 2.2% in the 4th quarter. Dimensional Fund Advisors LP now owns 164,763 shares of the medical device company’s stock valued at $19,738,000 after purchasing an additional 3,468 shares during the last quarter. Equitable Trust Co. lifted its position in DexCom by 2.4% in the 4th quarter. Equitable Trust Co. now owns 6,500 shares of the medical device company’s stock valued at $779,000 after purchasing an additional 150 shares during the last quarter. Finally, Nordea Investment Management AB bought a new stake in DexCom in the 4th quarter valued at about $441,000. 97.94% of the stock is owned by institutional investors.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.

Recommended Story: NASDAQ Stock Market Explained

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.